Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice

Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice

Aline David-Silva,1 João Victor Esteves,1 Mychel Raony PT Morais,2 Helayne Soares Freitas,1 Telma Maria Zorn,2 Maria Lucia Correa-Giannella,3 Ubiratan Fabres Machado1 1Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, S&atil...

Full description

Bibliographic Details
Main Authors: David-Silva A, Esteves JV, Morais MRPT, Freitas HS, Zorn TM, Correa-Giannella ML, Machado UF
Format: Article
Language:English
Published: Dove Medical Press 2020-03-01
Series:Diabetes, Metabolic Syndrome and Obesity
Subjects:
glut2
pepck
g6pase
phlorizin
nash.
Online Access:https://www.dovepress.com/dual-sglt1sglt2-inhibitor-phlorizin-ameliorates-non-alcoholic-fatty-li-peer-reviewed-article-DMSO

Internet

https://www.dovepress.com/dual-sglt1sglt2-inhibitor-phlorizin-ameliorates-non-alcoholic-fatty-li-peer-reviewed-article-DMSO

Similar Items